Collateral damage

Nature Biotechnology

Volumn 32, Issue 1, 2014, Pages 66-68

  Hancock, Robert E W ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFUROXIME; GENTAMICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG EFFICACY; DRUG USE; ESCHERICHIA COLI; HEALTH HAZARD; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 84892150785     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2779     Document Type: Article

References (9)

1. Boucher, H.W. et al. Clin. Infect. Dis. 48, 1-12 (2009).
2. HHS CDC. Antibiotic resistance threats in the United States, 2013 http://www.cdc.gov/drugresistance/threatreport-2013/pdf/ar-threats-2013-508.pdf (US Centers for Disease Control and Prevention, 2013).
3. Imamovic, L. & Sommer, M.O.A. Sci. Transl. Med. 5, 204ra132 (2013).
4. Fernandez, L., Breidenstein, E.B.M. & Hancock, R.E.W. Drug Resist. Updat. 14, 1-21 (2011).
5. Kalan, L. & Wright, G.D. Expert Rev. Mol. Med. 13, e5 (2011).
6. Hancock, R.E.W., Nijnik, A. & Philpott, D.J. Nat. Rev. Microbiol. 10, 243-254 (2012).
7. Defoirdt, T. PLoS Pathog. 9, e1003603 (2013).
8. Chung, G.W., Wu, J.E., Yeo, C.L., Chan, D. & Hsu, L.Y. Virulence 4, 151-157 (2013).
9. Pluchino, K.M., Hall, M.D., Goldsborough, A.S., Callaghan, R. & Gottesman, M.M. Drug Resist. Updat. 15, 98-105 (2012).